BNF for Children September 2022 Update

This update contains 7 significant changes, 3 dose changes, 5 new monographs, 1 new preparation, and 1 deleted preparation.

Significant Changes:

• Cystic fibrosis transmembrane conductance regulator modulators: update to hepatic impairment advice (see example in ivacaftor).
• Epilepsy: updated guidance on management.
• Hydrocortisone: addition of children’s dosing for adrenal crisis.
• Immunisation schedule: updated guidance for immunisation against influenza.
• Influenza vaccine: updated guidance for immunisation.
• Tezacaftor with ivacaftor and elexacaftor: name change to ivacaftor with tezacaftor and elexacaftor.
• Topiramate (Topamax®): start of safety review triggered by a study reporting an increased risk of neurodevelopmental disabilities in children with prenatal exposure [MHRA/CHM advice].

Dose Changes

• Briviact® (brivaracetam) [update to age range].
• Ivacaftor with tezacaftor and elexacaftor [update to age range].
• Tezacaftor with ivacaftor [update to age range].

New Monographs:

• Aklief® [trifarotene].
• Magnesium citrate.
• NovoThirteen® [factor XIII A-subunit (recombinant)].
• Palforzia® [peanut protein].
• Zepatier® [elbasvir with grazoprevir].

New Preparation:

• Assicco® [glycopyrronium bromide].

Deleted Preparation:

• Codeine phosphate solution for injection.

For further details on changes in the BNFC click on https://www.medicinescomplete.com/#/content/bnfc/PHP107699?hspl=changes